GSK - GlaxoSmithKline plc
| Previous Close | 40.98 |
| Open | 41.42 |
| Bid | 41.01 x 1300 |
| Ask | 41.64 x 3200 |
| Day's Range | 41.07 - 41.73 |
| 52 Week Range | 36.41 - 42.47 |
| Volume | 3,375,531 |
| Avg. Volume | 2,348,112 |
| Market Cap | 101.944B |
| Beta (3Y Monthly) | 0.55 |
| PE Ratio (TTM) | 41.52 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.86 (4.53%) |
| Ex-Dividend Date | 2019-08-08 |
| 1y Target Est | N/A |
- Business Wire
Nucala (mepolizumab) Gains FDA Approval for Two New Self-Administration Options
GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate. This is the first anti-IL5 biologic to be licensed in the US for at-home administration, and the first respiratory biologic to be approved for administration via an autoinjector. This approval will give healthcare professionals and people living with severe eosinophilic asthma (SEA) or the rare disease eosinophilic granulomatosis with polyangiitis (EGPA) the option for Nucala to be administered outside of a clinical setting by a patient or caregiver after their healthcare professional agrees this approach is appropriate.
- GlobeNewswire
Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.
- PR Newswire
Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK
Expands global footprint for complex API manufacturing WALTHAM, Mass. , May 16, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that ...
- GlobeNewswire
Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
- GlobeNewswire
New Research: Key Drivers of Growth for GlaxoSmithKline plc, nVent Electric, Dana, FMC, Qualys, and Affiliated Managers Group — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
- Business Wire
Pfizer and GlaxoSmithKline Announce Joint Venture to Create a Premier Global Consumer Healthcare Company
Pfizer Inc. (PFE) and GlaxoSmithKline plc (GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands. The Boards of Directors of both companies have unanimously approved the transaction under which Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business.
- ACCESSWIRE
Today's Research Reports on Trending Tickers: GlaxoSmithKline and bluebird bio
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / GlaxoSmithKline shares were in the red as Wall Street showed its concerns over the company announcing it would acquire Tesaro for around $5 billion. Shares of bluebird bio were also in the red despite reporting positive data from its LentiGlobin Gene Therapy study. GlaxoSmithKline plc shares were in the red on Monday despite big news that the company would be acquiring Tesaro, a pharmaceutical company based in Waltham, Massachusetts that has a focus on drug development for cancer.
- GlobeNewswire
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Tesaro, Inc. (TSRO) on Behalf of Stockholders and Encourages TSRO Investors to Contact the Firm
NEW YORK, Dec. 03, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Tesaro, Inc. (NASDAQ: TSRO) on behalf of.
- PR Newswire
Tesaro (TSRO) Alert: Johnson Fistel Investigates Proposed Sale of Tesaro, Inc. to GlaxoSmithKline plc; Are Shareholders Getting a Fair Deal?
SAN DIEGO , Dec. 3, 2018 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Tesaro, Inc. (NASDAQ: TSRO) ("Tesaro") ...
- GlobeNewswire
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). TESARO is a commercial-stage biopharmaceutical company, with a major marketed product, Zejula (niraparib), an oral poly ADP ribose polymerase (PARP) inhibitor currently approved for use in ovarian cancer. PARP inhibitors are transforming the treatment of ovarian cancer, notably demonstrating marked clinical benefit in patients with and without germline mutations in a BRCA gene (gBRCA).
- Business Wire
Once-daily Trelegy Ellipta gains expanded COPD indication in Europe
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (INVA) today announced that the European Commission has authorised an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), recognising its effect on exacerbations and making it the first single inhaler triple therapy indicated for patients with moderate to severe chronic obstructive pulmonary disease (COPD) not adequately treated with dual bronchodilation or with an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA). While bronchodilation is recognised as the foundation of COPD therapy, many patients may continue to struggle with symptoms and exacerbations over time.
- GlobeNewswire
Report: Developing Opportunities within Avon Products, Sanofi, Arch Coal, GlaxoSmithKline plc, Chimera Investment, and PTC — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE
Today's Research Reports on Trending Tickers: GlaxoSmithKline and Eli Lilly and Company
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...
- ACCESSWIRE
Today's Research Reports on Trending Tickers: Immunomedics and GlaxoSmithKline
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / U.S. equities finished mostly lower on Friday as earlier gains due to upbeat corporate earnings were hamstrung by a weakness in housing sales. According to ...